Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Colorectal Neoplasms 22Squamous Cell Carcinoma of Head and Neck 13Carcinoma, Non-Small-Cell Lung 12Neoplasms 6Rectal Neoplasms 5Neoplasm Metastasis 5Mouth Neoplasms 5Lung Neoplasms 5Head and Neck Neoplasms 5Colonic Neoplasms 5Pancreatic Neoplasms 4Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Carcinoma, Squamous Cell 3Carcinoma 3Thyroid Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Ovarian Neoplasms 2Oropharyngeal Neoplasms 2Endometrial Neoplasms 2Urologic Neoplasms 1Solid Tumors 1Soft Tissue Neoplasms 1Skin Neoplasms 1Sarcoma 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pharyngeal Neoplasms 1Neurofibromatosis 2 1Neurofibromatosis 1 1

Interventions

atezolizumab 2tocilizumab 1spartalizumab 1pembrolizumab 1fludarabine phosphate 1fludarabine 1adagrasib 1Trastuzumab 1Pemetrexed 1Oxaliplatin 1Nivolumab 1Leucovorin 1Irinotecan 1Fluorouracil 1Docetaxel 1Cyclophosphamide 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Tumors × Cetuximab × 30 days × Clear all
NCT07415031 2026-05-15

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

Mirati Therapeutics Inc.

Phase 2 Recruiting
170 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡